Compare LGIH & STAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | STAA |
|---|---|---|
| Founded | 2003 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2013 | 1995 |
| Metric | LGIH | STAA |
|---|---|---|
| Price | $58.80 | $25.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $75.90 | $22.81 |
| AVG Volume (30 Days) | 300.8K | ★ 993.6K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.25 | 0.26 |
| Revenue | ★ $1,705,504,000.00 | $239,442,000.00 |
| Revenue This Year | $2.32 | $30.82 |
| Revenue Next Year | $17.94 | $8.41 |
| P/E Ratio | ★ $45.11 | $94.77 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.55 | $15.59 |
| 52 Week High | $69.42 | $35.87 |
| Indicator | LGIH | STAA |
|---|---|---|
| Relative Strength Index (RSI) | 53.43 | 50.88 |
| Support Level | $55.45 | $25.24 |
| Resistance Level | $62.97 | $27.71 |
| Average True Range (ATR) | 2.77 | 1.38 |
| MACD | -0.09 | 0.27 |
| Stochastic Oscillator | 68.60 | 78.37 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.